What did @neverboringever actually say?
The creator's core claim is that her friend, a healthy 34-year-old athlete, suffered a near-fatal anaphylactic reaction five minutes after injecting a peptide she identifies as "Sir Morlin" or "Simarillin." She says the friend had taken peptides for about a year, experienced prior mild reactions at injection sites, and that this particular peptide had been used for several months before the severe event. The friend reportedly flatlined at the hospital.
She also claims that online forums contain "dozens of entries" of similar reactions, ranging from full-body hives to anaphylactic shock, and that mainstream information on peptide reactions is hard to find. Her intent is a safety warning, not a medical analysis. That framing matters when evaluating what she got right and what she got wrong.
Does the science back this up?
Anaphylaxis from injectable peptides is real and documented, even if rare. The broader risk is actually undersold in most peptide communities, so credit where it's due.
Anaphylaxis following peptide injection is biologically plausible. Peptides are immunogenic molecules, and repeated exposure can prime an IgE-mediated hypersensitivity response. A 2021 review by Descotes in Fundamental and Clinical Pharmacology confirmed that synthetic peptides, particularly those with non-natural amino acid sequences or carrier proteins, carry immunogenicity risk. The risk is amplified with unregulated compounded or gray-market products because contaminants, residual solvents, or incorrect reconstitution can act as adjuvants that heighten immune sensitization. The prior mild reactions the friend experienced, specifically hives and flushing, are textbook IgE sensitization signals that should have triggered a clinical pause. They didn't, which is a pattern seen repeatedly in unmonitored self-administration.
The peptide name she gives, "Sir Morlin" or "Simarillin," does not match any established peptide in peer-reviewed literature or common peptide registries, which creates a verification problem discussed below.
What did they get wrong (or right)?
She got the core warning right. She got the peptide identification almost certainly wrong, and she missed the most important safety mechanism that could have changed the outcome.
The prior mild reactions were not incidental. Repeated hives, flushing, and nausea after injections are recognized precursor symptoms of escalating hypersensitivity. A 2019 case series by Muraro et al. in Allergy documented that a significant proportion of severe anaphylaxis cases had prior mild reactions that were ignored or attributed to injection-site sensitivity. Recognizing these as warning signs and stopping use, or at minimum carrying epinephrine, is standard allergy protocol. No mention is made of an EpiPen anywhere in this account, which is the single most preventable gap in this story.
The peptide name is a real problem. "Simarillin" or "Sir Morlin" does not correspond to any documented peptide by that name. This may be a phonetic approximation of something like Sermorelin, a growth hormone-releasing hormone analogue. If so, that changes the clinical context significantly. Sermorelin is a 29-amino-acid peptide with a documented, if uncommon, hypersensitivity profile. Attributing the reaction to a misidentified compound makes the warning less useful, not more.
What should you actually know?
Gray-market injectable peptides carry real anaphylaxis risk, and most people using them are doing so without any allergy workup, no EpiPen access, and no physician oversight. That combination is dangerous.
A few things anyone currently using or considering injectable peptides should understand. First, injection-site reactions including hives, flushing, and nausea are not minor inconveniences. They are immune system signals. Continuing to inject after those symptoms appear without medical evaluation is the equivalent of ignoring a car's check-engine light while adding fuel. Second, compounded peptides from unregulated sources have no guaranteed sterility or purity. A 2020 analysis by Liang et al. in JAMA Internal Medicine found that a substantial portion of compounded injectable products tested contained incorrect concentrations or contaminants. Third, epinephrine auto-injectors are the first-line treatment for anaphylaxis. They are available by prescription. Any person injecting any compound, peptide or otherwise, without physician supervision should have a serious conversation about whether they should have one on hand. That is not a fringe position. It is standard allergy and emergency medicine practice.
- The creator is right that online peptide communities systematically minimize adverse reactions.
- She is right that severe outcomes can happen in healthy, experienced users.
- The peptide name she gives is likely incorrect, which limits the warning's clinical usefulness.
- The most actionable piece of information, carrying epinephrine, was never mentioned.